Uploaded January 2015 | Updated November 2026, 20 hours ago
This video tells the story of a Cochrane review which compared two treatments for macular degeneration - bevacizumab (brand name Avastin®) and intravitreal ranibizumab (brand name Lucentis®). It represents an important step forward in the knowledge about differences in systemic harms between these two drugs. Find out more about why, along with one story of how this Cochrane review has already made a difference.
Read the review here: cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-abs-0003
This video tells the story of a Cochrane review which compared two treatments for macular degeneration - bevacizumab (brand name Avastin®) and intravitreal ranibizumab (brand name Lucentis®). It represents an important step forward in the knowledge about differences in systemic harms between these two drugs. Find out more about why, along with one story of how this Cochrane review has already made a difference.
Read the review here: cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-abs-0003


![How to leverage social media as an early career researcher
Social media is more than just a communication tool. It can be a powerful platform for learning, networking, and career development.
In this Early Career Professional (ECP) Meet Up, Muriah Umoquit shares insights from managing Cochranes social media channels and discusses how early career professionals can use social media to connect with peers, share their expertise, and engage with global research communities. [youtube.com] How to leverage social media as an early career researcher](https://i.ytimg.com/vi/J_jgBSND35w/mqdefault.jpg)







